|
PE20191487A1
|
|
ANTI-GITR ANTIBODIES AND METHODS OF USE OF THEM
|
|
WO2016170447A1
|
|
Recombinant microbial transglutaminases
|
|
TW201630936A
|
|
Anti-pd-1 antibodies and methods of use thereof
|
|
WO2016075612A1
|
|
Inhibitory chimeric antigen receptors
|
|
EP3193928A1
|
|
Methods for reducing ldl-cholesterol
|
|
WO2016020799A1
|
|
Methods for reducing ldl-cholesterol
|
|
WO2015087187A1
|
|
Anti-sclerostin antibodies
|
|
WO2015015448A2
|
|
Engineered polypeptide conjugates using transglutaminase
|
|
CN105189560A
|
|
Anti-glucagon receptor antibodies and methods of use thereof
|
|
AU2014201648A1
|
|
Antagonist anti-il-7 receptor antibodies and methods
|
|
US2014017235A1
|
|
Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
|
|
MX2014007644A
|
|
Human growth hormone receptor antagonist antibodies and methods of use thereof.
|
|
WO2013093693A1
|
|
Staphylococcus aureus specific antibodies and uses thereof
|
|
CN104053672A
|
|
Antibodies specific for Trop-2 and their uses
|
|
WO2012080891A1
|
|
Anti-notch-1 antibodies
|
|
WO2012059882A2
|
|
Engineered polypeptide conjugates and methods for making thereof using transglutaminase
|
|
WO2011143545A1
|
|
Heterodimeric proteins and methods for producing and purifying them
|
|
AU2011201157A1
|
|
Anti-NGF antibodies and methods using same
|
|
TW201206466A
|
|
Antibodies with pH dependent antigen binding
|
|
TW201132356A
|
|
Antagonist anti-il-7 receptor antibodies and methods
|
